Find uplifting stories about heroes, innovations, and solutions
8 results for "leqembi"
Families in rural Kansas no longer need to drive hours to Kansas City for breakthrough Alzheimer's therapy. Wamego Health Center is bringing hope closer to home with a treatment that slows disease progression.
The FDA just approved LEQEMBI IQLIK, the first Alzheimer's treatment patients can give themselves at home from day one. The weekly autoinjector takes just 15 seconds per dose and could transform how millions manage early Alzheimer's disease. #
A clinical trial for a new Alzheimer's treatment shows dramatically lower rates of dangerous brain swelling compared to current drugs. The results could offer hope for safer treatment options for millions of families facing this disease.
Researchers finally solved the mystery of how lecanemab, an approved Alzheimer's drug, actually works in the brain. The discovery could lead to safer treatments for the 55 million people living with dementia worldwide.
Four promising new treatments could reach patients this spring, offering fresh hope for people battling hard-to-treat conditions. From the first-ever medication for a chronic liver infection to an at-home Alzheimer's treatment, these therapies represent real progress for patients who've been waiting.
Massachusetts researchers are using artificial intelligence to catch Alzheimer's disease years earlier than traditional methods, when new treatments work best. The breakthrough could help millions get diagnosed before symptoms become severe.
Scientists discovered that a single brain protein called SORLA protects against both toxic plaques and tangles that destroy brain cells in Alzheimer's disease. Mice with higher SORLA levels showed less brain damage and healthier neurons, offering new hope for treating dementia.
A simple blood test can now predict who will develop Alzheimer's disease up to a decade before symptoms appear. Combined with a new at-home treatment option, this breakthrough could transform care for patients across South Carolina and beyond.